Annovis Bio, Inc. (ANVS)
PHARMACEUTICAL PREPARATIONS
Annovis Bio, Inc. (ANVS) is listed on the New York Stock Exchange, where it has traded since January 29, 2020.
- Listed On
- the New York Stock Exchange
- Listed Since
- January 29, 2020
- Employees
- 7
- Market Cap
- $54M
About Annovis Bio, Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 59 institutions reported holding ANVS, with 10.9 million shares worth $20.2 million in aggregate. The largest reported holder was Empery Asset Management, with 2.4 million shares worth $4.5 million. Of the 5 largest holders listed below, 2 opened new positions in ANVS and 3 added shares during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Empery Asset Management | 2,401,476 | $4M | New position |
| Marshall Wace | 1,842,339 | $3M | Added 55.14% |
| Vanguard | 1,836,042 | $3M | Added 80.78% |
| Tudor Investment Corp | 1,357,134 | $3M | New position |
| Renaissance Technologies | 1,002,200 | $2M | Added 188.32% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ANVS?
Annovis Bio, Inc. (ANVS) is listed on the New York Stock Exchange, where it has traded since January 29, 2020.
Who are the largest institutional holders of ANVS?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ANVS were Empery Asset Management, Marshall Wace and Vanguard.
How many institutions own ANVS?
59 institutions reported a position in ANVS for the quarter ended June 30, 2026, worth $20.2 million in total.
Did institutions buy or sell ANVS last quarter?
Of the 5 largest reported holders, 2 opened new positions in ANVS and 3 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for ANVS.
Every reported institutional holder, plus insider and congressional trades in ANVS, on SentiSense.